Format

Send to

Choose Destination
Oncogene. 2014 Dec 11;33(50):5675-87. doi: 10.1038/onc.2013.513. Epub 2013 Dec 9.

CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells.

Author information

1
ManRos Therapeutics, Hôtel de Recherche, Centre de Perharidy, Roscoff, France.
2
Evotec (München) GmbH, Am Klopferspitz 19a, Martinsried, Germany.
3
1] ManRos Therapeutics, Hôtel de Recherche, Centre de Perharidy, Roscoff, France [2] C.N.R.S., 'Protein Phosphorylation & Human Disease' Group, Station Biologique, B.P. 74, Roscoff cedex, Bretagne, France.
4
C.N.R.S., 'Protein Phosphorylation & Human Disease' Group, Station Biologique, B.P. 74, Roscoff cedex, Bretagne, France.
5
Laboratoire de Chimie Organique 2, INSERM U 648, Université Paris-Descartes, 4 avenue de l'Observatoire, Paris cedex, France.
6
Cancer Sciences & Clinical and Experimental Medicine, University of Southampton, Institute for Life Sciences, Center for Proteomics & Metabolomics Research, Highfield Campus, Southampton, UK.
7
Institute for Computational Biomedicine, Weil Cornell Medical College, New York, NY, USA.
8
Department of Tumor Cell Biology, St Jude Children's Research Hospital, 332 North Lauderdale, Memphis, TN, USA.
9
CNRS UMR 6290-Institut de Génétique et Développement de Rennes, Equipe Expression des Gènes et Oncogenèse, Université de Rennes1, SFR Biosit, Faculté de Médecine, 2 avenue du Pr. Léon Bernard, Rennes cedex, France.

Abstract

To understand the mechanisms of action of (R)-roscovitine and (S)-CR8, two related pharmacological inhibitors of cyclin-dependent kinases (CDKs), we applied a variety of '-omics' techniques to the human neuroblastoma SH-SY5Y and IMR32 cell lines: (1) kinase interaction assays, (2) affinity competition on immobilized broad-spectrum kinase inhibitors, (3) affinity chromatography on immobilized (R)-roscovitine and (S)-CR8, (4) whole genome transcriptomics analysis and specific quantitative PCR studies, (5) global quantitative proteomics approach and western blot analysis of selected proteins. Altogether, the results show that the major direct targets of these two molecules belong to the CDKs (1,2,5,7,9,12), DYRKs, CLKs and CK1s families. By inhibiting CDK7, CDK9 and CDK12, these inhibitors transiently reduce RNA polymerase 2 activity, which results in downregulation of a large set of genes. Global transcriptomics and proteomics analysis converge to a central role of MYC transcription factors downregulation. Indeed, CDK inhibitors trigger rapid and massive downregulation of MYCN expression in MYCN-amplified neuroblastoma cells as well as in nude mice xenografted IMR32 cells. Inhibition of casein kinase 1 may also contribute to the antitumoral activity of (R)-roscovitine and (S)-CR8. This dual mechanism of action may be crucial in the use of these kinase inhibitors for the treatment of MYC-dependent cancers, in particular neuroblastoma where MYCN amplification is a strong predictor factor for high-risk disease.

PMID:
24317512
PMCID:
PMC4087096
DOI:
10.1038/onc.2013.513
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center